D. Novick

发表

Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study

J. Haro, D. Naber, J. Marques-Teixeira, 2008, International clinical psychopharmacology.

Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review

A. Liepa, U. Kiiskinen, L. Hess, 2015, Journal of medical economics.

Financing health care in Europe: context for the Schizophrenia Outpatient Health Outcomes Study

M. Knapp, D. McDaid, C. Curran, 2003, Acta psychiatrica Scandinavica. Supplementum.

Regional differences in treatment response and three year course of schizophrenia across the world.

J. Lépine, J. Haro, E. Alvarez, 2012, Journal of psychiatric research.

Predictors of the course of illness in outpatients with schizophrenia: A prospective three year study

J. Haro, S. Ochoa, D. Suarez, 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study

J. Haro, T. Treuer, S. Kraemer, 2015, BMC Psychiatry.

Relationship of Insight with Medication Adherence and the Impact on Outcomes in Patients with Schizophrenia and Bipolar Disorder: Results From A 1-Year European Outpatient Observational Study.

J. Haro, T. Treuer, S. Kraemer, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A systematic literature review of prognostic factors in patients with HR+/HER2− advanced breast cancer in Japan

J. Haro, Kana Takaura, H. Iwata, 2021, Japanese journal of clinical oncology.

Real-World Treatment Patterns and Health-Resource Utilization in Patients with Hepatocellular Carcinoma (HCC) Following Failure of Sorafenib: A Retrospective Chart Review of 127 Patients in South Korea

S. Colman, D. Novick, A. Szende, 2021, Drugs - Real World Outcomes.

Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia

J. Haro, H. Ascher-Svanum, J. Aguado, 2012, Quality of Life Research.

[Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years].

J. Haro, J. Alonso, M. Bousoño, 2008, Actas espanolas de psiquiatria.

Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?

J. Haro, R. Brugnoli, Z. Kadziola, 2013, Patient preference and adherence.

Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study

S. Tjulandin, P. Thompson-Leduc, W. Cheng, 2019, Journal of Drug Assessment.

Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil

C. Beato, E. Minowa, D. Novick, 2018, Journal of Gastrointestinal Cancer.

Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine

W. Shen, D. Faries, S. Able, 2013, Journal of medical economics.

Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study

J. Haro, M. Bousoño, A. Montejo, 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Worldwide‐Schizophrenia Outpatient Health Outcomes (W‐SOHO): baseline characteristics of pan‐regional observational data from more than 17,000 patients *

J. Haro, T. Treuer, J. Pečeňák, 2009, International journal of clinical practice.

Rates and predictors of remission and recovery during 3 years in 392 never‐treated patients with schizophrenia

M. Lambert, D. Naber, H. Hundemer, 2008, Acta psychiatrica Scandinavica.

Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia: Thirty-Six-Month Results From the European Schizophrenia Outpatient Health Outcomes Study

J. Haro, P. Haddad, D. Novick, 2010, Journal of clinical psychopharmacology.

Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan.

R. Cheng, S. Colman, D. Novick, 2022, Value in health regional issues.

Poster #207 LONG-TERM FUNCTIONAL IMPROVEMENTS IN THE 2-YEAR TREATMENT OF SCHIZOPHRENIA OUTPATIENTS WITH OLANZAPINE LONG-ACTING INJECTION

J. Haro, H. Ascher-Svanum, H. Detke, 2012, Schizophrenia Research.

PMH25 CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NONADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/ MIXED EPISODE OF BIPOLAR DISORDER: RESULTS FROM THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUDY

J. Haro, J. Aguado, D. Novick, 2009 .

Symptomatic remission and patient quality of life in an observational study of schizophrenia: Is there a relationship?

J. Haro, M. Knapp, E. Perrin, 2014, Psychiatry Research.

Clinical meaningful outcomes in schizophrenia: remission and recovery.

L. San, J. Bobes, E. Alvarez, 2011, Revista de psiquiatria y salud mental.

Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in

J. Haro, T. Treuer, W. Montgomery, 2014 .

Olanzapine vs. other antipsychotics in actual out‐patient settings: six months tolerability results from the European Schizophrenia Out‐patient Health Outcomes study

M. Lambert, D. Naber, M. Ratcliffe, 2005, Acta psychiatrica Scandinavica.

Incidence of diabetic peripheral neuropathic pain in primary care – a retrospective cohort study using the United Kingdom General Practice Research Database

M. Happich, D. Novick, Jihyung Hong, 2013, Pragmatic and observational research.

Schizophrenia Outpatient Health Outcomes (W-SOHO) study Cross-national clinical and functional remission rates: Worldwide

J. Haro, M. Dossenbach, D. Novick, 2011 .

Impact of painful physical symptoms on depression outcomes in elderly Asian patients

J. Haro, R. Brugnoli, Xiaomei Peng, 2014, International Psychogeriatrics.

Factors Predicting Hostility in Outpatients With Schizophrenia: 36-Month Results From the SOHO Study

J. Haro, B. Arranz, S. Ochoa, 2013, The Journal of nervous and mental disease.

Sex differences in the course of schizophrenia across diverse regions of the world

J. Haro, T. Treuer, M. Moneta, 2016, Neuropsychiatric disease and treatment.

J. Haro, M. Moneta, W. Montgomery, 2015, Patient preference and adherence.

Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review

D. Novick, A. Cruz, S. Campos-Gómez, 2019, PharmacoEconomics - Open.

Lost in transition: A review of the unmet need of patients with attention deficit/hyperactivity disorder transitioning to adulthood

T. Treuer, B. Semerci, D. Wynchank, 2017, Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists.

Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice

M. Tohen, J. Haro, A. González-Pinto, 2010, International clinical psychopharmacology.

Validity and Reliability of the Hamilton Depression Rating Scale (5 Items) for Manic and Mixed Bipolar Disorders

J. Haro, F. Mosquera, S. Barbeito, 2009, The Journal of nervous and mental disease.

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study

J. Haro, W. Montgomery, D. Novick, 2015, Neuropsychiatric disease and treatment.

“Voluntary” User Fees in Buenos Aires Hospitals: Innovation or Imposition?

P. Lloyd-Sherlock, D. Novick, 2001, International journal of health services : planning, administration, evaluation.

Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms

J. Haro, T. Treuer, M. Moneta, 2017, Pharmacopsychiatry.

Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.

J. Haro, D. Suarez, D. Novick, 2009, Journal of psychiatric research.

Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study

J. Lépine, J. Haro, M. Lambert, 2007, Psychopharmacology.

Which somatic symptoms are associated with an unfavorable course in Chinese patients with major depressive disorder?

J. Haro, R. Brugnoli, J. Aguado, 2015, Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists.

The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.

Roy W Jones, B. Vellas, J. Haro, 2013, Journal of Alzheimer's disease : JAD.

The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

Peter B. Jones, J. Haro, J. Orta, 2003, Acta psychiatrica Scandinavica. Supplementum.

Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study

J. Lépine, J. Haro, I. Gasquet, 2005, International clinical psychopharmacology.

Effectiveness of antipsychotic treatment for schizophrenia: 6‐month results of the Pan‐European Schizophrenia Outpatient Health Outcomes (SOHO) study

Peter B. Jones, J. Haro, A. Breier, 2005, Acta psychiatrica Scandinavica.

The Cost of Relapse for Patients with a Manic/Mixed Episode of Bipolar Disorder in the EMBLEM Study

J. Haro, F. Windmeijer, M. Knapp, 2012, PharmacoEconomics.

Duloxetine for the treatment of painful diabetic peripheral neuropathy in Venezuela: economic evaluation.

D. Flores, F. Carlos, D. Novick, 2015, Medwave.

Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients

J. Haro, J. Aguado, W. Montgomery, 2016, Neuropsychiatric disease and treatment.

Comparative Effectiveness in Terms of Treatment Discontinuation of Orodispersable Versus. Standard Oral Olanzapine Tablets in Non-Adherent Patients: Results from a 1-Year European Outpatient Observational Study.

J. Haro, T. Treuer, S. Kraemer, 2014, Value in Health.

Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder

J. Haro, A. Koyanagi, T. Treuer, 2017, Patient preference and adherence.

Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study

J. Haro, M. Bortolomasi, R. Brugnoli, 2012, BMC Psychiatry.

Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study

J. Haro, J. Aguado, D. Novick, 2011, Psychiatry Research.

The economic burden of advanced gastric cancer in Taiwan

Jen‐Shi Chen, R. Cheng, D. Novick, 2017, BMC Health Services Research.

Impact of pain and remission in the functioning of patients with depression in Mainland China, Taiwan, and Hong Kong

J. Haro, S. Siddi, M. Moneta, 2018, Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists.

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study

J. Haro, M. Moneta, E. Vorstenbosch, 2017, Patient preference and adherence.

Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East

J. Haro, M. Moneta, D. Novick, 2017, Clinical practice and epidemiology in mental health : CP & EMH.

Chinese patients with major depression: Do concomitant pain symptoms affect quality of life independently of severity of depression?

J. Haro, R. Brugnoli, M. Moneta, 2015, International journal of psychiatry in clinical practice.

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline

J. Haro, Y. Fang, M. Moneta, 2018, Neuropsychiatric disease and treatment.

Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea

Hyo Song Kim, C. Nam, S. Rha, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea

S. Colman, D. Novick, A. Szende, 2022, Journal of drug assessment.

The Number Needed to Treat for All-Cause Medication Discontinuation in the Treatment of Schizophrenia: Consistency Across World Geographies and Study Designs

H. Ascher-Svanum, A. Brnabic, E. Perrin, 2009, Pharmacopsychiatry.

Remission and Relapse in the Outpatient Care of Schizophrenia: Three-year Results From the Schizophrenia Outpatient Health Outcomes Study

J. Lépine, J. Haro, D. Suarez, 2006, Journal of clinical psychopharmacology.

The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study

J. Haro, F. Windmeijer, D. Novick, 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia

Josep Maria Haro, Victor Perez, J. Haro, 2010, Psychiatry Research.

Health care costs before and after diagnosis of depression in patients with unexplained pain: a retrospective cohort study using the United Kingdom General Practice Research Database

Catherine Reed, Michael Happich, Jihyung Hong, 2013, ClinicoEconomics and outcomes research : CEOR.

Costs Associated With Treatment of Chronic Low Back Pain: An Analysis of the UK General Practice Research Database

M. Happich, D. Novick, Jihyung Hong, 2013, Spine.

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study

J. Haro, R. Brugnoli, M. Dossenbach, 2012, BMC Psychiatry.

Schizophrenia Outpatient Health Outcomes study: twelve-month findings

J. Haro, H. Ascher-Svanum, Michihiro Takahashi, 2012, Pragmatic and observational research.

Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results

J. Haro, D. Naber, J. Usall, 2007, European Neuropsychopharmacology.

I. Gasquet, M. Knapp, T. Croudace, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Caregiving for patients with Alzheimer's disease or dementia and its association with psychiatric and clinical comorbidities and other health outcomes in Brazil

J. Laks, A. Goren, K. Kahle-Wrobleski, 2016, International journal of geriatric psychiatry.

Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia

P. Sun, D. Novick, J. Andrews, 2014, Journal of pain research.

Predictors of duloxetine adherence and persistence in patients with fibromyalgia

D. Faries, D. Novick, Z. Cui, 2012, Journal of pain research.

Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study

J. Haro, D. Naber, E. Vieta, 2009, Schizophrenia Research.

Factors associated with and impact of pain persistence in Asian patients with depression: a 3-month, prospective observational study

J. Haro, J. Aguado, W. Montgomery, 2017, International journal of psychiatry in clinical practice.

Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review

D. Novick, Kyla Jones, Miguel Quintana, 2017, PharmacoEconomics - Open.

A Rasch model analysis to test the cross‐cultural validity of the EuroQoL‐5D in the Schizophrenia Outpatient Health Outcomes Study

L. Prieto, E. Edgell, D. Novick, 2003, Acta psychiatrica Scandinavica. Supplementum.

Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study

Peter B. Jones, J. Haro, M. Dossenbach, 2011, British Journal of Psychiatry.

Originals Remission and relapse in the ambulatory treatment of patients with schizophrenia . Outcomes at 3 years

J. Haro, M. Bousoño, D. Suarez, 2008 .

Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study

J. Haro, D. Suarez, E. Perrin, 2009, European Neuropsychopharmacology.

Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non‐adherent patients with schizophrenia

J. Haro, R. Brugnoli, D. Novick, 2013, Human psychopharmacology.

Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications

J. Haro, P. Haddad, D. Novick, 2012, International clinical psychopharmacology.

The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain

J. Haro, M. Bousoño, D. Suarez, 2008, European Psychiatry.

Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

Peter B. Jones, J. Haro, M. Belger, 2006, European Psychiatry.

Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania--results of a two year observational study in bipolar disorder (EMBLEM).

J. Haro, E. Vieta, A. González-Pinto, 2011, Journal of affective disorders.

Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia

J. Haro, T. Treuer, W. Montgomery, 2014, BMC Psychiatry.

Direct Medical Costs and Medication Compliance among Fibromyalgia Patients: Duloxetine Initiators vs. Pregabalin Initiators

D. Faries, P. Sun, D. Novick, 2014, Pain practice : the official journal of World Institute of Pain.

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study

J. Haro, H. Ascher-Svanum, H. Detke, 2013, BMC Psychiatry.

Observational study designs for bipolar disorder — What can they tell us about treatment in acute mania?

J. Haro, A. González-Pinto, D. Novick, 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies.

J. Haro, S. Ochoa, D. Suarez, 2008, Journal of clinical epidemiology.

Differential 3-Year Effects of First- Versus Second-Generation Antipsychotics on Subjective Well-Being in Schizophrenia Using Marginal Structural Models

J. Haro, M. Lambert, D. Naber, 2011, Journal of clinical psychopharmacology.

Assessment of Medication Adherence in a Cohort of Patients with Bipolar Disorder

J. Haro, A. González-Pinto, D. Novick, 2010, Pharmacopsychiatry.

Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia

J. Haro, T. Treuer, W. Montgomery, 2013, Patient preference and adherence.

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan

T. Takano, J. Tsurutani, M. Onishi, 2023, Breast Cancer.

Incidence and characteristics of remission in schizophrenic patients: analysis of the results of the three-year SOHO study in Italy (Schizophrenia Outpatients Health Outcomes)

A. Rossi, J. Haro, R. Brugnoli, 2008 .

Impact of Negative Symptoms on Quality of Life in Patients with Schizophrenia.

J. Haro, W. Montgomery, D. Novick, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Which somatic symptoms are associated with an unfavorable course in Asian patients with major depressive disorder?

J. Haro, R. Brugnoli, Z. Kadziola, 2013, Journal of affective disorders.

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

M. Witte, H. Ascher-Svanum, D. Faries, 2011, European Psychiatry.

Reply to Letter on: Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia: 36-Month Results From the European SOHO Study

D. Novick, 2011 .

Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study

J. Haro, F. Windmeijer, M. Knapp, 2012, PharmacoEconomics.

Should Unexplained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms?

J. Haro, J. Aguado, W. Montgomery, 2015, Clinical practice and epidemiology in mental health : CP & EMH.

Retrospective analysis of patients with advanced or metastatic gastric cancer in Colombia

J. Haro, S. Siddi, M. Moneta, 2019, Journal of medical economics.

Utilization of duloxetine and celecoxib in osteoarthritis patients

Shih-Yin Chen, D. Novick, N. Wu, 2013, Current medical research and opinion.

Real‐world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia

J. Haro, M. Moneta, W. Montgomery, 2016, Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists.

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia

J. Haro, R. Brugnoli, G. Zhu, 2016, Neuropsychiatric disease and treatment.

Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective

D. Faries, D. Novick, Z. Cui, 2012, Journal of medical economics.

Determinants of Voluntary vs. Involuntary Admission in Bipolar Disorder and the Impact of Adherence

D. Schuepbach, D. Hell, H. Boeker, 2008, Pharmacopsychiatry.

Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine

D. Faries, D. Novick, Z. Cui, 2011, Journal of medical economics.

Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care

Shih-Yin Chen, D. Novick, N. Wu, 2013, Journal of pain research.

2-year course of bipolar disorder type I patients in outpatient care: Factors associated with remission and functional recovery

J. Haro, E. Vieta, A. González-Pinto, 2011, European Neuropsychopharmacology.

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia

J. Haro, V. Pérez, R. Dittmann, 2010, Psychiatry Research.

Translation of Randomised Controlled Trial Findings into Clinical Practice: Comparison of Olanzapine and Valproate in the EMBLEM Study

M. Tohen, J. Haro, A. González-Pinto, 2009, European Psychiatry.

Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China

J. Jackson, S. Cotton, D. Novick, 2023, Pain and Therapy.

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

J. Haro, H. Ascher-Svanum, H. Detke, 2014, Neuropsychiatric disease and treatment.

Antidepressant medication treatment patterns in Asian patients with major depressive disorder

J. Haro, R. Brugnoli, W. Montgomery, 2015, Patient preference and adherence.

Worldwide‐Schizophrenia Outpatient Health Outcomes (W‐SOHO): baseline characteristics of pan‐regional observational data from more than 17,000 patients *

J. Haro, T. Treuer, J. Pečeňák, 2009, International journal of clinical practice.

The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study

J. Haro, F. Windmeijer, D. Novick, 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Caregiving for patients with Alzheimer's disease or dementia and its association with psychiatric and clinical comorbidities and other health outcomes in Brazil

J. Laks, A. Goren, K. Kahle-Wrobleski, 2016, International journal of geriatric psychiatry.

Schizophrenia Outpatient Health Outcomes study: twelve-month findings

J. Haro, H. Ascher-Svanum, Michihiro Takahashi, 2012 .

Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study

S. Evers, J. Pascual, D. Novick, 2023, The Journal of Headache and Pain.

Antipsychotic Monotherapy and Polypharmacy in the Treatment of Outpatients With Schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study

J. Haro, H. Ascher-Svanum, R. Brugnoli, 2012, The Journal of nervous and mental disease.